Get the Stockscreener App
2.85
3.06%
-0.09
After Hours:
3.00
0.15
+5.26%
Inmed Pharmaceuticals Inc stock is traded at $2.85, with a volume of 10,364.
It is down -3.06% in the last 24 hours and down -7.17% over the past month.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
See More
Previous Close:
$2.94
Open:
$2.89
24h Volume:
10,364
Relative Volume:
0.02
Market Cap:
$3.61M
Revenue:
$4.96M
Net Income/Loss:
$-6.82M
P/E Ratio:
-0.0436
EPS:
-65.4
Net Cash Flow:
$-6.64M
1W Performance:
-5.00%
1M Performance:
-7.17%
6M Performance:
-54.65%
1Y Performance:
-65.16%
1-Day Range:
$2.85
$2.9882
1-Week Range:
$2.66
$3.18
52-Week Range:
$2.414
$15.70
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
Name
Inmed Pharmaceuticals Inc
Sector
Phone
(604) 669-7207
Address
1445-885 WEST GEORGIA ST., VANCOUVER
Compare INM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
2.85 | 3.61M | 4.96M | -6.82M | -6.64M | -65.40 |
|
ZTS
Zoetis Inc
|
170.53 | 75.15B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.58 | 47.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.84 | 47.70B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.00 | 18.75B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.28 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
Inmed Pharmaceuticals Inc Stock (INM) Latest News
InMed Pharmaceuticals Struggles with Losses Amid Revenue Decline - MSN
InMed Pharmaceuticals Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update - Defense World
InMed Pharmaceuticals Board Reshuffle After Director Resignation - TipRanks
InMed Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update - Yahoo Finance
InMed Pharmaceuticals Inc. (INM) reports earnings - Quartz
InMed Pharmaceuticals Inc. SEC 10-Q Report - TradingView
InMed's Mixed Q2 Results Reveal Hidden Gem: Subsidiary Turns 189% Profit as Pipeline Advances - StockTitan
InMed Advances INM-089 for Dry AMD Treatment with New Intravitreal Formulation - TipRanks
Inmed selects IVT formulation of INM-089 for dry AMD - BioWorld Online
InMed advances AMD treatment with promising IVT drug formulation - MSN
Revolutionary Eye Drug INM-089 Achieves 10X Therapeutic Levels in Macular Degeneration Treatment - StockTitan
Inmed Pharmaceuticals Inc (INM-Q) QuotePress Release - The Globe and Mail
InMed Pharmaceuticals (NASDAQ: INM) Secures International Patent for Novel Compounds - Defense World
InMed Pharmaceuticals Secures Key Patent for Cannabinoid Analogs - TipRanks
InMed Pharmaceuticals secures international patent - Investing.com India
InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds - Newsfile
InMed Secures Breakthrough 20-Year Patent in Mexico for Novel Cannabinoid Compounds - StockTitan
InMed Pharmaceuticals (NASDAQ: INM) Announces Positive Results from INM-901 Alzheimer’s Disease Study - Defense World
Nano-Cap InMed Ignites Retail Frenzy As Stock Soars After Alzheimer's Drug Trial Shows Promise - MSN
InMed Hails Alzheimer's Study, Stocks Shoot Higher - Baystreet.ca
InMed announces ‘positive’ results from in vivo preclinical Alzheimer’s study - TipRanks
InMed’s INM-901 Shows Promising Results in Preclinical Alzheimer’s Study - TipRanks
InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study - Newsfile
SABBY MANAGEMENT, LLC Acquires Shares in InMed Pharmaceuticals I - GuruFocus.com
InMed Pharmaceuticals Inc. Holds 2024 Annual General Meeting – Elects Directors and Appoints Auditor - Defense World
InMed Pharmaceuticals Director Faces Resignation After Shareholder Vote at Annual Meeting - StockTitan
InMed Announces Results of 2024 Annual General Meeting - Newsfile
InMed Pharmaceuticals Inc. announced that it expects to receive CAD 10 million in funding - Marketscreener.com
InMed Enters Into Standby Equity Purchase Agreement - Newsfile
Head-To-Head Review: InMed Pharmaceuticals (NASDAQ:INM) & Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
InMed Pharmaceuticals Secures $10M Equity Purchase Agreement in Strategic Financing Move - StockTitan
InMed Pharmaceuticals (TSE:IN) Trading Down 1.6% – Time to Sell? - Defense World
InMed Pharmaceuticals (FRA:MWG) Altman Z-Score : -14.86 (As of Dec. 05, 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Altman Z-Score : -14.90 (As of Dec. 03, 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Inventories, Finished Goods : €0.84 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Shares Outstanding (EOP) : 0.67 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Total Liabilities : $2.07 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Debt-to-Equity : 0.13 (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Dividend Yield % : 0.00% (As of Nov. 26, 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Dividend Payout Ratio : 0.00 (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) EBITDA : $-6.66 Mil (TTM As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Cash, Cash Equivalents, Marketa - GuruFocus.com
INM (InMed Pharmaceuticals) Growth Rank : 0 (As of Nov. 26, 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Machinery, Furniture, Equipment : $0.04 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) 3-Year EPS without NRI Growth R - GuruFocus.com
INM (InMed Pharmaceuticals) Total Inventories : $1.22 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Net Income : $-6.82 Mil (TTM As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Inventory Turnover : 0.63 (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Revenue per Share : $49.03 (TTM As of Sep. 2024) - GuruFocus.com
Inmed Pharmaceuticals Inc Stock (INM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.25%
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):